The CRYOcheck FVIII Inhibitor Kit is for clinical laboratory use in conjunction
The CRYOcheck FVIII Inhibitor Kit is for clinical laboratory use in conjunction with a factor VIII activity assay to enable performance of a modified Nijmegen-Bethesda assay using 3.2% citrated human plasma. It enables the determination of a functional FVIII inhibitor titer to aid in the clinical management of congenital hemophilia A in individuals aged 2 years and older.
GGN,GGP
Plasma, Coagulation Control,Test, Qualitative And Quantitative Factor Deficiency
CRYOcheck Chromogenic Factor VIII is for clinical laboratory use in the quantita
CRYOcheck Chromogenic Factor VIII is for clinical laboratory use in the quantitative determination of factor VIII activity in 3.2% citrated human plasma. It is intended to be used in identifying factor VIII deficiency and as an aid in the management of hemophilia A in individuals aged 2 years and older. For in vitro diagnostic use
GGP
Test, Qualitative And Quantitative Factor Deficiency
Prepared from human source plasma and recommended as a negative control in assay
Prepared from human source plasma and recommended as a negative control in assays for lupus anticoagulant.
Prepared from human source plasma and recommended as a negative control in assay
Prepared from human source plasma and recommended as a negative control in assays for lupus anticoagulant.
CRYOcheck Hex LA is for clinical laboratory use as a qualitative test kit intend
CRYOcheck Hex LA is for clinical laboratory use as a qualitative test kit intended to aid in the detection of lupus anticoagulants (LA) in 3.2% citrated human plasma by the application of hexagonal phase phospholipids. CRYOcheck Hex LA should be used as an integrated test for lupus anticoagulant detection. For in vitro diagnostic use. The performance of this device has not been established in neonate and pediatric patient populations.
A pool of normal citrated human plasma collected from a minimum of 20 donors, bu
A pool of normal citrated human plasma collected from a minimum of 20 donors, buffered with 0.05M HEPES and stabilizers, dispensed and lyophilized. This plasma is used for the quality control of coagulation assays in the normal range, including fibrinogen, coagulation factors II, V, VII, VIII, IX, X XI and XII, ATIII activity, Protein C activity and Protein S activity.
A pool of citrated normal human plasma collected from a minimum of 20 donors, an
A pool of citrated normal human plasma collected from a minimum of 20 donors, and diluted to defined concentrations. Plasma is buffered with 0.05M HEPES and stabilizers, dispensed and lyophilized. This plasma is used for the quality control of coagulation assays in the normal range, including fibrinogen, coagulation factors II, V, VII, VIII, IX, X XI and XII, ATIII activity, Protein C activity and Protein S activity.
A pool of citrated human plasma collected from a minimum of 20 donors that has b
A pool of citrated human plasma collected from a minimum of 20 donors that has been depleted of specific clotting factors. The plasma is buffered with 0.05M HEPES buffer and stabilizers, dispensed and lyophilized. This plasma is used for the quality control of coagulation assays (PT and APTT) in the highly abnormal range.
A pool of citrated human plasma collected from a minimum of 20 donors that has b
A pool of citrated human plasma collected from a minimum of 20 donors that has been depleted of specific clotting factors. The plasma is buffered with 0.05M HEPES buffer and stabilizers, dispensed, and lyophilized. This plasma is used for the quality control of coagulation assays (PT and APTT) in the mid-level abnormal range.
A pool of normal citrated human plasma collected from a minimum of 20 donors, bu
A pool of normal citrated human plasma collected from a minimum of 20 donors, buffered with 0.05M HEPES buffer and stabilizers, dispensed and lyophilized. This plasma is used for the quality control of coagulation assays (PT, APTT and Fibinogen) in the normal range.
Intended for use in the quality control of quantitative coagulation assays, incl
Intended for use in the quality control of quantitative coagulation assays, including Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) in the mid-level abnormal range.
Intended for use in the quality control of quantitative coagulation assays, incl
Intended for use in the quality control of quantitative coagulation assays, including Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT), in the mid-level abnormal range.
Intended for use in the quality control of quantitative coagulation assays, incl
Intended for use in the quality control of quantitative coagulation assays, including Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT), in the mid-level abnormal range.
Intended for use in the quality control of quantitative coagulation assays, incl
Intended for use in the quality control of quantitative coagulation assays, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and Fibrinogen, in the normal range.
Intended for the use in the quality control of quantitative coagulation assays,
Intended for the use in the quality control of quantitative coagulation assays, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and Fibrinogen, in the normal range.
Intended for the use in quality control of quantitative coagulation assays, incl
Intended for the use in quality control of quantitative coagulation assays, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and Fibrinogen, in the normal range.
Intended for use in the quality control of coagulation assays in the borderline
Intended for use in the quality control of coagulation assays in the borderline pathological range.
Intended for use in the quality control of coagulation assays in the borderline
Intended for use in the quality control of coagulation assays in the borderline pathological range.